Trending Now
Headline
Health care has had a tough year. Where we stand on our 5 stocks in the sector
Health Gorilla launches Patient Access, Enabling Access to
Aging With a Healthy Brain: How Lifestyle Changes Could Help Prevent up to 40% of Dementia Cases
Analysis: Shein vows to cut clothing waste, but can the ultra-fast fashion brand really change its spots?
‘Mastermind’ arrested after alleged Ont. operation involving 300 people
How health systems can better protect patient privacy
Health Workers Warn Loosening Mask Advice in Hospitals Would Harm Patients and Providers
‘They’re meaningless’: why women’s clothing sizes don’t measure up | Fashion
Saint Regis Mohawk Tribe and NYS Department of Health Strengthen Relationship

Medical Product Alert N°7/2023: Falsified DEFITELIO (defibrotide)

Health Advice
admin

Medical Product Alert N°7/2023: Falsified DEFITELIO (defibrotide)


Alert Summary

This WHO Medical Product Alert refers to one falsified batch of DEFITELIO (defibrotide sodium). This falsified product has been detected in India (April 2023) and Türkiye (July 2023) and was supplied outside of regulated and authorized channels.

DEFITELIO (defibrotide) is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated for adults, adolescents, children and infants over 1 month of age. VOD is a condition in which the veins in the liver become blocked and stop the liver working correctly.

The genuine manufacturer of DEFITELIO has confirmed that the product referenced in this Alert is falsified. The genuine manufacturer has advised that:

  • Genuine DEFITELIO with Lot 20G20A was packaged in German/Austrian packaging.
  • The falsified products instead are in UK/Ireland packaging.
  • The stated expiry date is falsified and does not comply with the registered shelf life.
  • The stated serial number is not associated with batch 20G20A.
  • DEFITELIO does not have marketing authorization in India and Türkiye.

WHO has previously issued Alerts for falsified DEFITELIO detected in other Countries and Regions. Please refer to Medical Product Alert N°5/2020, and Medical Product Alert N°3/2023.

Please refer to the Annex of this Alert for full details of the affected products.

Risks

The use of falsified DEFITELIO will result in the ineffective treatment of patients and may pose other serious risks to health because of its intravenous administration and could be life-threatening in some circumstances.

WHO is not currently aware of any reports of adverse events following the use of this reported falsified DEFITELIO, however, the safety, sterility, and quality of the falsified products referenced in this alert are unknown. 

Advice to regulatory authorities and the public

If you have any of the affected products, WHO recommends that you do not use them. If you, or someone you know, has or may have used the affected product, or suffered an adverse reaction or unexpected side-effect after use, you are advised to seek immediate medical advice from a healthcare professional.

Healthcare professionals should report the incident to the National Regulatory Authorities/National Pharmacovigilance Centre. National regulatory/health authorities are advised to immediately notify WHO if they identify these falsified products.

All medical products must be obtained from authorized/licensed suppliers. If you have any information about the manufacture or supply of these products, please contact WHO via [email protected]. 

Please see Annex for details of the substandard product referenced in Alert N°7/2023.

 

WHO Global Surveillance and Monitoring System   

 

 

 

 



Source link

Back To Top